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The evolutionarily conserved target of rapamycin
(TOR) signaling controls growth, metabolism, and
aging. In the first robust demonstration of phar-
macologically-induced life extension in mammals,
longevity was extended in mice treated with rapamy-
cin, an inhibitor of mechanistic TOR (mTOR). How-
ever, detrimental metabolic effects of rapamycin
treatment were also reported, presenting a paradox
of improved survival despite metabolic impairment.
How rapamycin extended lifespan in mice with
such paradoxical effects was unclear. Here we
show that detrimental effects of rapamycin treatment
were only observed during the early stages of treat-
ment. These effects were reversed or diminished in
mice treated for 20 weeks, with better metabolic
profiles, increased oxygen consumption and keto-
genesis, and markedly enhanced insulin sensitivity.
Thus, prolonged rapamycin treatment lead to benefi-
cial metabolic alterations, consistent with life exten-
sion previously observed. Our findings provide a
likely explanation of the ‘‘rapamycin paradox’’ and
support the potential causal importance of these
metabolic alterations in longevity.
INTRODUCTION
mTOR (mechanistic target of rapamycin) is a master regulator of
growth and metabolism. It senses upstream inputs of growth
factors (such as insulin), nutrients, and energy status to regulate
downstream events by its complex 1 (mTORC1) and/or its com-
plex 2 (mTORC2) (Wullschleger et al., 2006). Rapamycin inhibits
mTORC1, but longer rapamycin treatment also affects mTORC2
(Sarbassov et al., 2006). With various genetic backgrounds,
extension of longevity was reported in mice with knockout of
S6K1, a target of mTOR (Selman et al., 2009), and in mice fed
(Harrison et al., 2009) or injected (Chen et al., 2009; Anisimov
et al., 2011) with rapamycin, but rapamycin treatment was
repeatedly reported to produce detrimental metabolic changes
usually associated with reduced rather than extended longevity,
including insulin resistance, hyperlipidemia, and glucose intoler-
ance (Houde et al., 2010; Chang et al., 2009; Fraenkel et al.,456 Cell Metabolism 17, 456–462, March 5, 2013 ª2013 Elsevier Inc.2008). Thus, it remains unclear how rapamycin extends the
lifespan of mice. In various studies, the length of rapamycin
treatment ranged from 2 (Houde et al., 2010; Fraenkel et al.,
2008) or 6 weeks (Chen et al., 2009; Chang et al., 2009) to 1.5–
2 years (Harrison et al., 2009; Anisimov et al., 2011), when rapa-
mycin led to longer survivorship. We hypothesized that these
paradoxical findings might be due to differences in the duration
of treatment and that longer rapamycin treatment might change
the metabolic parameters controlled by insulin signaling toward
a beneficial profile. To test this hypothesis, we compared the
effects of injecting adult male mice with rapamycin for 2, 6, or
20 weeks. Indeed, the mice experienced negative effects of
rapamycin treatment, including insulin resistance with short
duration, but insulin signaling changed from an insulin resis-
tant to an insulin-sensitive state after 20 weeks of rapamycin
treatment.RESULTS
Duration of Rapamycin Treatment Changed Body
Features
Starting at an age of 3 months, the male mice were injected with
rapamycin for 2, 6, or 20 weeks according to the protocol by
Chen et al. (2009) and were then sacrificed when rapamycin
treatments were completed. With 2 or 6 weeks of rapamycin
treatment, adiposity, body weight (BW), and food consumption
were not altered; however, after 20 weeks of treatment, they
were reduced dramatically (Figures 1A, 1D, 1F, and 1G and Fig-
ure S1A available online) without significant changes in lean body
mass (Figures 1E and S1B). Prolonged rapamycin treatment pre-
vented normal body weight gain (Figures 1D and 1F) mainly due
to decreased adiposity (Figure 1A, S1A, 1E, and S1B and data
not shown). Pancreas mass was reduced after 2 weeks of rapa-
mycin treatment but was restored with 20 weeks of treatment
(Figures 1B and S1C). Liver mass was increased after 2 weeks
of rapamycin treatment, but it no longer differed from that
of controls after 20 weeks of treatment (Figures 1C and S1D).
Thus, body features associated with metabolic syndrome, in-
cluding smaller pancreas and enlarged liver, appeared in the
mice with 2 weeks of rapamycin treatment, but with continued
treatment these features returned to normal levels, and adi-
posity, body weight, and food consumption were decreased.
Themost striking differences between the effects of short versus
prolonged rapamycin treatment concern insulin signaling, glu-
cose and lipid homeostasis, and metabolism.
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Figure 1. Body Characteristics Alter with
Duration of Rapamycin Treatment
(A) Relative total fat mass [absolute value (g) / body
weight (g)]3 100. Total fat includes subcutaneous
fat from the thighs, a pair of perigonadal (visceral)
depots, a pair of perinephric depots, and inter-
scapular brown fat.
(B) Relative mass of the pancreas.
(C) Relative mass of the liver.
(D) Body weight.
(E) Relative total lean mass [absolute value
(g)/body weight (g)] 3 100. Total lean mass is
estimated as follows: lean mass = body weight –
total fat mass.
(F) Time course of body weight measured over
20 weeks of rapamycin treatment.
(G) Time course of food consumption over
19 weeks of rapamycin treatment.
Data are means ± SEM (n = 8–16 for control, n =
9–16 for rapamycin). p values were calculated
between the rapamycin-treated and control
groups at each time point independently. The error
bars represent the SEM. *p % 0.05, **p % 0.01,
***p% 0.001. See also Figure S1.
Cell Metabolism
Length of Treatment May Explain Rapamycin ParadoxProlonged Rapamycin Treatment Increased Insulin
Sensitivity
Insulin signaling is important in the control of longevity in both
mice and humans, although the specific mechanisms are not
completely understood and some findings are controversial
(Barzilai et al., 2012). Normally, insulin inhibits hepatic gluconeo-
genesis and increases lipogenesis. In individuals exhibiting
insulin resistance, excess insulin is produced as a compensatory
mechanism. When insulin resistance develops, insulin initially
loses its ability to inhibit hepatic gluconeogenesis but maintains
the ability to enhance lipogenesis. As a result, hyperglycemia
and hypertriglyceridemia occur (Matsumoto et al., 2006).
mTORC1 is required for insulin-induced stimulation of lipogen-
esis but not for inhibition of gluconeogenesis (Li et al., 2010),
and 2 weeks of rapamycin treatment inhibited lipogenesis and
upregulated gluconeogenesis (Houde et al., 2010). Similarly,
2 weeks of rapamycin treatment in our study increased insulin
levels 2.5-fold compared with controls (Figure 2A). The mice
became glucose intolerant (Figure 2D) and insulin resistant (Fig-Cell Metabolism 17, 456–4ure 2E), with increased glucose (Figure 2B
and Table S1) and HOMA-IR (homeo-
static model for assessment of insulin
resistance) levels (Figure 2C). However,
with 6 weeks of rapamycin treatment,
the mice experienced a transition from
insulin resistance toward an improved
metabolic state (Figure 2A–2C, 2F, and
2G and Table S1). Strikingly, with
20 weeks of rapamycin treatment, both
insulin levels and insulin sensitivity were
altered in a direction opposite to that
observed with 2 weeks of treatment:
insulin levels decreased (Figure 2A), while
insulin sensitivity increased (Figure 2I)
drastically compared with the controls.Although glucose intolerance remained, especially at the early
stage of the glucose tolerance test (GTT; Figure 2H), HOMA-IR
values derived from both insulin and glucose levels were signif-
icantly reduced (Figure 2C). These findings indicate that with
prolonged rapamycin treatment, the mice progressed from
being insulin resistant to having improved insulin sensitivity.
Prolonged Rapamycin Treatment Improved Lipid Profile
and Metabolism
Lipid homeostasis showed similar but more complex responses.
Lipolysis breaks down triglycerides into glycerol and free fatty
acids (measured as nonesterified fatty acids [NEFAs]), and lipo-
genesis generates triglycerides. Insulin inhibits lipolysis but
enhances lipogenesis. Consequently, when insulin levels are
high, less glycerol and NEFAs and more triglycerides are gener-
ated (Prentki and Madiraju, 2012). In our study, after 2 weeks of
rapamycin treatment, the mice had increased insulin levels (Fig-
ure 2A), likely explaining lower glycerol (Figure 3A) and higher
triglycerides (Figure 3C). After 6 weeks of rapamycin treatment,62, March 5, 2013 ª2013 Elsevier Inc. 457
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Figure 2. Insulin Signaling and Glucose
Homeostasis Switch from Insulin Resistant
State with Short Rapamycin Treatment to
Insulin Sensitive State with Prolonged
Rapamycin Treatment
(A) Plasma insulin levels.
(B) Fasted glucose levels.
(C) Homeostatic model for assessment of insulin
resistance (HOMA-IR). HOMA-IR = (FPI 3 FPG) /
22.5, where FPI is fasted plasma insulin and FPG
is fasted plasma glucose. Plasma and fasted
glucose values were collected at sacrifice.
(D, F, and H) Glucose tolerance test (GTT).
Sixteen-hour-fasted mice underwent GTT by
intraperitoneal (i.p.) injection with 1 g glucose per
kg of BW.
(E, G, and I) Insulin tolerance test (ITT). Mice were
i.p. injected with 1 IU porcine insulin per kg of BW.
Data are mean ± SEM (n = 8–16 for control, n =
9–16 for rapamycin). p values were calculated
between the rapamycin-treated and control
groups at each time point independently. The error
bars represent the SEM.*p % 0.05, **p % 0.01,
***p% 0.001. See also Figure S2 and Table S1.
Cell Metabolism
Length of Treatment May Explain Rapamycin Paradoxincrease in insulin levels was much less pronounced, but insulin
was still higher than in controls (Figure 2A); glycerol and NEFA
levels were suppressed (Figures 3A and 3B), while triglycerides
remained elevated (Figure 3C). In contrast, after 20 weeks of
rapamycin treatment, insulin levels were reduced significantly
(Figure 2A) and triglycerides declined to control levels (Fig-
ure 3C). Thus, also with regard to lipid homeostasis, the duration
of rapamycin treatment determined the direction of the changes.
Similar to the findings in human renal transplant patients, who458 Cell Metabolism 17, 456–462, March 5, 2013 ª2013 Elsevier Inc.received rapamycin as an immunosup-
pressant for 12 months (Blum, 2002),
hypertriglyceridemia detected after short
rapamycin treatment was normalized
when the treatment was continued for
20 weeks. Although the mice treated
with rapamycin for 20 weeks no longer
had hypertriglyceridemia, they could
have had elevated levels of free fatty
acids, reflecting enhanced lipolysis and
reduced lipogenesis. Elevation of free
fatty acids is associated with the meta-
bolic syndrome (Prentki and Madiraju,
2012). Interestingly, NEFA levels were
not increased by 20 weeks of rapamycin
treatment (Figure 3B). What other lipid
metabolic changes could have developed
with 20 weeks of rapamycin treatment
to produce a decrease of free fatty
acids? Adipose-specific knockout of
Raptor results in mice being lean due
to enhanced oxygen consumption (VO2)
without affecting respiratory quotient
(RQ) (Polak et al., 2008). Could the mice
treated with rapamycin for 20 weeks in
our study have higher oxygen consump-tion (VO2) to burn more fatty acids? Similar to the previous report
(Cunningham et al., 2007), the mice with 2 weeks of rapamycin
treatment had reduced VO2 (Figure 3D), suggesting that they
expend less energy. An intermediate state was observed in
mice treated with rapamycin for 6 weeks, such that VO2 was
not significantly different from the controls (Figure 3E). In
contrast, after 20 weeks of rapamycin treatment, the mice had
higher VO2 than the controls (Figure 3F), suggesting that they
expend more energy, which was consistent with the findings in
Co
n 
(2
 w
k)
Ra
p 
(2
 w
k)
Co
n 
(6
 w
k)
Ra
p 
(6
 w
k)
Co
n 
(2
0 
wk
)
Ra
p 
(2
0
wk
)
0.0
0.2
0.4
0.6
0.8
1.0
Con
Rap*** *
G
ly
c
e
ro
l
(m
g
/d
l)
A
Co
n 
(2
 w
k)
Ra
p 
(2
 w
k)
Co
n 
(6
 w
k)
Ra
p 
(6
 w
k)
Co
n 
(2
0 
wk
)
Ra
p 
(2
0
wk
)
0.7
0.8
0.9
1.0
1.1
*
N
E
F
A
(m
m
o
l/
L
)
B
Co
n (
2 w
k)
Ra
p (
 2
wk
)
Co
n (
6 w
k)
Ra
p (
6 w
k) 
Co
n (
20
 w
k)
Ra
p (
20
 w
k) 
0
100
200
300
400
500
600
700 **
To
ta
l K
et
on
e
(µ
M
) 
G
7P
M
9P
M
11
PM 1A
M
3A
M
5A
M
7A
M
9A
M
11
AM 1P
M
3P
M
5P
M
35
45
55
65
75
85
95
105
115
Con
Rap
VO
2
(m
l/k
g/m
in)
Co
n
Ra
p
0
50
100
150
200
250
Con
Rap
Ar
ea
un
de
rc
ur
ve
E
Time
6 weeks 
7P
M
9P
M
11
PM 1A
M
3A
M
5A
M
7A
M
9A
M
11
AM 1P
M
3P
M
5P
M
35
40
45
50
55
60
65
70
Rap
Con
VO
2
(m
l/k
g/m
in)
F
Co
n
Ra
p
50
60
70
80
90
100
110
120
Con
Rap***
Ar
ea
un
de
rc
ur
ve
20 weeks 
7P
M
9P
M
11
PM 1A
M
3A
M
5A
M
7A
M
9A
M
11
AM 1P
M
3P
M
5P
M
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
Con
Rap
VO
2(
ml
/kg
/m
in)
D
Co
n 
Ra
p 
100
150
200
250
300
350
Con
Rap***
Ar
ea
un
de
rc
ur
ve
2 weeks 
Time
Co
n 
(2
 w
k)
Ra
p 
(2
 w
k)
Co
n 
(6
 w
k)
Ra
p 
(6
 w
k)
Co
n 
(2
0 
wk
)
Ra
p 
(2
0
wk
) 
60
80
100
120
140 ** *
T
ri
g
ly
ce
ri
d
e
s
(m
g
/d
L
)
C
Time
Figure 3. Lipid Profile, Oxygen Consump-
tion, and Total Ketone Body Production
Chang after Different Lengths of Rapamycin
Treatment
(A) Plasma glycerol levels.
(B) Plasma NEFA levels.
(C) Plasma triglycerides levels. For plasma chem-
ical analysis, mice were fasted for 16 hr, and thusly
collected plasma was subjected to the assays.
(D–F) Oxygen consumption VO2 (ml/kg/min) mea-
sured via indirect calorimetry (AccuScan Instru-
ments, Columbus, OH) after 2 weeks (D), 6 weeks
(E), or 20 weeks (F) of rapamycin treatment. Data
are mean ± SEM (n = 8 for control or rapamycin).
(G) Plasma total ketone bodies. Mice were fasted
for 16 hr, and plasma total ketone bodies were
measured with total ketone body kits (Wako,
Richmond, VA). Data aremean ± SEM (n = 8–16 for
control, n = 9–16 for rapamycin).
The error bars represent the SEM.*p% 0.05, **p%
0.01, ***p% 0.001.
Cell Metabolism
Length of Treatment May Explain Rapamycin Paradoxmice with adipose-specific knockout of Raptor (Polak et al.,
2008). Duration of rapamycin treatment did not alter RQ (Fig-
ure S2) or spontaneous locomotor activity (data not shown).
The present findings indicate that as the length of rapamycin
treatment increased from 2 and 6 to 20 weeks, the energy
metabolism was switched from lower energy expenditure and
reliance on carbohydrates to higher energy expenditure and
increased reliance on burning fatty acids. Fatty acid breakdown
is also related to ketogenesis. mTOR was reported to control
fasting-induced ketogenesis, and this process was linked to
modulation of aging (Sengupta et al., 2010). Could it be possible
that with 20 weeks of rapamycin treatment the mice also haveCell Metabolism 17, 456–4enhanced ketogenesis in our study?
Indeed, the levels of total ketone bodies
were not altered after 2 or 6 weeks of
rapamycin treatment but were signifi-
cantly increased when the treatment
was continued for 20 weeks (Figure 3G).
Both mTORC1 and mTORC2 Were
Involved inMetabolic Alterations by
Duration of Rapamycin Treatment
Given the metabolic alterations we
observed, it is crucial to know whether
duration of the treatment changed the
levels or effectiveness of rapamycin.
With the same biochemical readout of
rapamycin effectiveness used by Harri-
son et al. (2009), phosphorylation of ribo-
somal protein subunit S6 in liver was
analyzed. The blood levels of rapamycin
(Figure 4C) and inhibition of phosphoryla-
tion of S6 with longer rapamycin treat-
ment (Figures 4A and 4B) were similar to
those reported by Harrison et al. (2009).
However, both the levels of rapamycin
and inhibition of pS6 were not altered
with duration of the treatments (Figure 4).Although S6 is a remote downstream target of mTORC1, the
metabolic switch caused by duration of the treatments was not
differentially regulated at the level of pS6. To test whether the
regulation was upstream of S6 and whether mTORC2 was also
involved, we measured mTOR, Raptor (a key component of
mTORC1), Rictor (a key component of mTORC2), S6K1 and
4EBP1 (direct downstream targets of mTORC1), and AKT
(a downstream target of mTORC2). Duration of rapamycin treat-
ment did not change the levels of these proteins. Two weeks of
rapamycin treatment reduced phosphorylation of mTOR, S6K1,
4EBP1, and AKT and 6 weeks of the treatment led to the transi-
tion stage, while 20 weeks of rapamycin treatment had reverse62, March 5, 2013 ª2013 Elsevier Inc. 459
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Figure 4. Effects of Different Duration of
Rapamycin Treatment on the Blood Levels
of Rapamycin and Phosphorylation of S6 in
the Liver
(A) Western blots of S6 and phosphorylation of S6
at S240/244. Western blots are representative of
three independent experiments. Each treatment
includes six samples from six individual animals.
(B) Quantification of the western blots. Data are
means ± SEM (n = 6).
(C) Blood levels of rapamycin. Data are means ±
SEM (n = 4–6).
p values were calculated between the rapamycin-
treated and control groups at each time point
independently. Different letters represent p %
0.05. The error bars represent the SEM. See also
Figures S3 and S4.
Cell Metabolism
Length of Treatment May Explain Rapamycin Paradoxeffects, compared with shorter rapamycin treatments (Figures
S3 and S4). Thus, various measures of insulin signaling and its
downstream metabolic effects changed drastically from unfa-
vorable after 2 or 6 weeks of rapamycin treatment toward largely
beneficial after 20weeks of rapamycin treatment. In other words,
duration of rapamycin treatment emerges as a key determinant
of not only the magnitude but, importantly, also the direction of
the responses.
DISCUSSION
The terms ‘‘prolonged’’ or ‘‘chronic’’ used to describe rapamycin
treatment in various studies have been confusing. Several
studies used a period of 2 to 6 weeks as prolonged or chronic ra-
pamycin treatment (Houde et al., 2010; Chang et al., 2009;
Fraenkel et al., 2008), while much longer periods of exposure460 Cell Metabolism 17, 456–462, March 5, 2013 ª2013 Elsevier Inc.(1.5–2 years) showed the ability of rapa-
mycin to extend longevity (Harrison
et al., 2009; Anisimov et al., 2011).
Although various genetic backgrounds
of mice, as well as various diets and
methods of rapamycin administration,
were used in the previous studies (Houde
et al., 2010, Lamming et al., 2012), our
2 weeks of rapamycin treatment showed
similar detrimental effects of short rapa-
mycin treatment on insulin signaling and
related downstream events. Results of
6 weeks of rapamycin treatment generally
resembled the effects of 2 weeks of
rapamycin treatment but appeared to
represent a transitional state with regard
to insulin sensitivity and HOMA-IR. In
contrast, 20 weeks of rapamycin treat-
ment had very different and generally
‘‘beneficial’’ effects, which may be a
mechanism of extended longevity in
mice by rapamycin (Harrison et al.,
2009; Anisimov et al., 2011). The present
study differed from the previous report
by Harrison et al. (2009) in the geneticbackground of the mice, the source and composition of the
diet, and the route of rapamycin administration; however, both
studies involved long-term treatment with rapamycin and utilized
a diet with a similar fat content (5.0% versus 4.6%), and both
used genetically heterogeneous mice with partial commonality
in the strains from which they were derived.
Rapamycin inhibition of mTOR signaling is primarily due to
its actions on mTORC1, although prolonged rapamycin treat-
ment also affects mTORC2. Hepatic mTORC2 was reported to
mediate rapamycin-induced insulin resistance; however, short
(2 to 4 weeks) rapamycin treatment in mice with hepatic Rictor
deletion caused a further pronounced increase of insulin and
glucose levels (Lamming et al., 2012). These data indicate that
the actions of mTORC1 and mTORC2 might not be fully sepa-
rate, and instead it may be their balance that determines the final
impact on insulin signaling and longevity (Hughes and Kennedy,
Cell Metabolism
Length of Treatment May Explain Rapamycin Paradox2012). Our biochemical data showed that duration of rapamycin
treatment affected not only levels of phosphorylation of mTOR,
S6K1, 4EBP1, and AKT, but also direction of the responses.
Based on our data, we speculated that both mTORC1 and
mTORC2 played roles in these differential responses (Figures
S3 and S4 and data not shown). Unexpectedly, considering
the similar blood levels of rapamycin and inhibition of pS6
(Figure 4), prolonged rapamycin treatments in themice no longer
inhibited levels of pmTOR, pS6K1, p4EBP1, or pAKT, while it
remained effective in inhibiting pS6 (Figures S3 and S4). The
molecular mechanism for the disparate responses of pS6K1
and pS6 remains unclear. However, S6K2 could also play a
significant role, as S6K2, not S6K1, is the predominant kinase
for S6 phosphorylation (Pende et al., 2004). In addition, phos-
phorylation of S6K1 at T389 is not the only regulatorymechanism
for phosphorylation of S6. Nevertheless, the striking difference in
the insulin signaling responses might well underlie the distinct
physiological effects and might potentially explain why pro-
longed rapamycin treatment is beneficial. The exact mecha-
nisms of the counterintuitive signaling outcome upon prolonged
rapamycin treatment will be investigated in future studies.
In the present study, alterations in insulin sensitivity induced
by different durations of rapamycin treatment were closely asso-
ciated with changes of glucose and lipid homeostasis and
metabolism, as well as body composition. After 20 weeks of
rapamycin treatment, the mice were lean with enhanced insulin
sensitivity (measured by insulin tolerance test [ITT]; Figure 2I),
increased oxygen consumption and ketogenesis, and improved
serum lipid profile. The mice with prolonged rapamycin treat-
ments showed a certain degree of glucose intolerance, espe-
cially at the early stages of GTT (Figure 2H), but those mice
were able to clear glucose, albeit at a slower pace due to lower
basal levels of insulin and higher insulin sensitivity (Figures 2A
and 2I). Most of these phenotypic features are associated with
extended longevity in several kinds of mutant mice (Bartke,
2005) and therefore can be viewed as candidate mechanisms
of life extension in animals exposed to rapamycin (Harrison
et al., 2009; Anisimov et al., 2011). In support of this suggestion,
deletion of S6K1 attenuated age-related loss of insulin sensitivity
and increased lifespan in mice (Selman et al., 2009). By showing
differences between metabolic responses to short versus long-
term rapamycin treatment, the present findings provide a likely
explanation of the paradox of reported detrimental effects of
rapamycin on insulin signaling and its ability to extend longevity.
EXPERIMENTAL PROCEDURES
Mice Maintenance
The animal procedures were approved by the Laboratory Animal Care andUse
Committee of Southern Illinois University School of Medicine. Mice were
housed under temperature- and light-controlled conditions (22C ± 1C,
12 hr light/12 hr dark cycle) with ad libitum access to food (Chow 5001 with
23.4% protein, 5% fat, and 5.8% crude fiber; LabDiet PMI Feeds, St. Louis,
MO). Our breeding colony was developed by mating of mice with 129 Ola/
BALB/c background with mice derived from crossing of C57BL/6 and C3H
strains and thereafter breeding of the resulting animals in a closed colony
without brother 3 sister matings. The colony generated thus has a heteroge-
neous genetic background. Beginning at the same age (3 months), male
mice were injected i.p. with 4 mg/kg BW rapamycin (LC labs, Woburn, MA)
or vehicle every other day according to the protocol by Chen et al. (2009)
and were then sacrificed after 2, 6, or 20 weeks of rapamycin treatment.CeGlucose Tolerance Test and Insulin Tolerance Test
Sixteen-hour-fasted mice underwent GTT by i.p. injection with 1 g glucose per
kg of BW.Blood glucose levels weremeasured at 0, 15, 30, 45, 60, and 120min
with a PRESTO glucometer (AgaMatrix, Salem, NH) for GTT. Nonfasted mice
were injected i.p. with 1 IU porcine insulin (Sigma, St. Louis, MO) per kg of
BW. Blood glucose levels were measured at 0, 15, 30, and 60 min for ITT.
The data for both ITT and GTT are presented as a percentage of baseline
glucose.
Indirect Calorimetry
Mice injected for 2, 6, or 20 weeks with rapamycin were subjected to
indirect calorimetry (AccuScan Instruments, Columbus, OH). The system
uses zirconia, infrared sensors and light beam arrays to monitor oxygen
consumption (VO2), carbon dioxide output (VCO2), and spontaneous loco-
motor activity inside respiratory chambers in which individual mice were
tested. After 24 hr acclimation, mice were monitored in the chambers for
24 hr with ad libitum access to food (Chow 5001; LabDiet PMI Feeds) and
water. All comparisons are based on animals studied simultaneously in eight
different chambers connected to the same O2, CO2, and light beam sensors.
Gas samples were collected and analyzed every 5 min per animal, and the
data were averaged for each hour.
Assessment of Blood Chemistry
After 2, 6, or 20 weeks of rapamycin treatment, mice were fasted for 16 hr and
sacrificed. Plasma was collected at sacrifice. Per the manufacturer’s protocol,
insulin was measured with Mouse Insulin ELISA Kits (Crystal Chem, Downers
Grove, IL), total ketone bodies and NEFAs were measured via colorimetric
assays from Wako Chemicals (Richmond, VA), glycerol was measured with
kits from Sigma (St. Louis, MO), and triglycerides were measured with kits
from Pointe Scientific (Canton, MI). The whole-blood samples were used to
measure rapamycin levels using HPLC-tandem MS as detailed in the Supple-
mental Experimental Procedures.
Western Blot Analysis
Mice were fasted for 16 hr. Plasma was collected, and then half of the animals
from each experimental group were injected with insulin or saline through the
liver portal vein to stimulate insulin signaling pathway with a previously
described protocol (Bonkowski et al., 2009). Two minutes after insulin injec-
tion, mice were sacrificed and the liver tissues were collected. Approximately
500 mg liver samples were homogenized in 0.5 ml ice-cold T-PER tissue
protein extraction buffer (Thermo Scientific, Rockford, IL) with protease and
phosphatase inhibitors (Sigma). Total protein (40 mg) was separated by SDS-
PAGE with Criterion XT Precast Gel (Bio-Rad, Hercules, CA) and blotted
with the antibodies. Antibodies, including mTOR, phospho-mTOR (Ser2448),
Raptor, phospho-Raptor (Ser792), Rictor, phospho-Rictor (Thr1135), S6K1,
phospho-S6K1(Thr389), 4EBP1, phospho-4EBP1(Ser65), AKT, phospho-
AKT(Ser473), S6, phospho-S6 (Ser240/244), and GAPDH, were obtained
from Cell Signaling Technology (Beverly, MA). Western blots were quantified
with Multi Gauge V3.0 software (Fujifilm North America, Edison, NJ).
Statistical Analysis
Data are presented as means ± SEM. The error bars represent SEM. Differ-
ences between two groups were assessed with unpaired two-tailed Student’s
t tests. All statistical analyseswere conducted with SPSSStatistics 17.0 (SPSS
Company, Quarry Bay, Hong Kong).
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.cmet.2013.02.008.
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